This article is more than 5 years old. Information may no longer be current.

Clearside completes enrollment in phase 2 Tanzanite trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Enrollment in a phase 2 clinical trial of CLS-TA and Eylea for treatment of macular edema associated with retinal vein occlusion is complete, according to a press release from Clearside Biomedical Inc.

The Tanzanite trial is intended to evaluate safety and efficacy of a single injection of CLS-TA (triamcinolone acetonide) delivered via the suprachoroidal space (SCS) combined with an initial intravitreal injection of aflibercept (Eylea, Regeneron).

The primary efficacy endpoint is the number of patients eligible for additional aflibercept treatments, and secondary efficacy endpoints include change in visual acuity and reduction in retinal thickness from baseline, according to the release.

“We believe SCS drug administration of CLS-TA, in combination with a VEGF inhibitor, could reduce the frequency of required RVO treatments from monthly to quarterly,” Daniel H. White, Clearside president and CEO, said in the release.